A randomized phase 3 study of ivonescimab plus chemotherapy versus pembrolizumab plus chemotherapy for the first-line treatment of metastatic non–small cell lung cancer: HARMONi-3. This is an ASCO ...
Everyday Health on MSN
6 tips to conserve energy and combat fatigue when you have non-small cell lung cancer
Use these six lifestyle habits to conserve energy and fight fatiue during the day.
New ELCC 2026 data show longer survival, better brain metastases control and more personalized treatment options for patients ...
Recent research is helping to expand the potential biomarker landscape in non–small cell lung cancer (NSCLC) and may soon ...
Early survival results from the first stage of a phase 3 study suggest that gotistobart, a new antibody associated with anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), has potential as a ...
Patients with non-squamous non-small cell cancer may achieve similar outcomes with a subcutaneous formulation of the immunotherapy toripalimab as with IV administration.
Asia-Pacific promises rapid growth, while increasing tobacco use and investments in oncology centers drive demand for innovative treatments Non-Small Cell Lung Cancer (NSCLC) Market Non-Small Cell ...
ORR 35.8% overall, 37.5% in second-/third-line, and 47.1% in light/nonsmokers, with median DOR not reached in key subsets.
Nuvation Bio Inc. (NYSE:NUVB) is one of the Best Stocks Under $10 to Buy and Hold Forever. On March 27, Nuvation Bio Inc.
Sunvozertinib is the first targeted oral treatment for NSCLC with EGFR exon 20 insertion mutations, approved for post-chemotherapy progression cases. The WU-KONG1 Part B study showed a 53.3% objective ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results